Johnson & Johnson has submitted its esketamine for regulatory approval, but researchers still don't understand how the fast-acting antidepressant lifts moods.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Essential role of microglial transforming growth factor-β1 in antidepressant actions of (R)-ketamine and the novel antidepressant TGF-β1
Translational Psychiatry Open Access 27 January 2020
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
PowerPoint slides
Rights and permissions
About this article
Cite this article
Reardon, S. 'Party drug' turned antidepressant approaches approval. Nat Rev Drug Discov 17, 773–775 (2018). https://doi.org/10.1038/nrd.2018.187
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2018.187
This article is cited by
-
Efficacy of anticonvulsant ethosuximide for major depressive disorder: a randomized, placebo-control clinical trial
European Archives of Psychiatry and Clinical Neuroscience (2021)
-
Essential role of microglial transforming growth factor-β1 in antidepressant actions of (R)-ketamine and the novel antidepressant TGF-β1
Translational Psychiatry (2020)